Survival trends in elderly patients with glioblastoma multiforme: Resective surgery, radiation, and chemotherapy

Patwardhan, Ravish V.; Shorter, Cedric; Willis, Brian K.; Reddy, P. Madhusudhana; Smith, Donald R.; Caldito, Gloria; Nanda, Anil

doi:10.1016/j.surneu.2003.11.016

Cited by 34 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, however, no correlation has been found between age and prognosis. Recently, there has been a significant improvement in the survival of elderly patients with GBM, thanks to the introduction of aggressive treatments [23][24][25]. In the present series, no statistically significant difference was observed in age-related survival probability.…”

Section: Discussioncontrasting

confidence: 60%

Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy

Matsuda¹,

Yamamoto²,

Ishikawa³

et al. 2011

BJR

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to evaluate the influence of prognostic factors related to patient selection on survival outcomes. Survival outcomes were retrospectively analysed in a consecutive series of 67 newly diagnosed glioblastoma multiforme (GBM) patients who had received either conventional fractionated photon radiotherapy (CRT) or high-dose particle radiotherapy (HDT). In the CRT protocol, a total dose of 60.0-61.2 Gy was administered. In the HDT protocol, an average dose of approximately 30 GyE in a single session and additional fractionated photon irradiation of total dose 30 Gy were administered to patients receiving boron neutron capture therapy; and a total dose of 96.6 GyE was administered to patients receiving proton therapy. Most of the patients had received chemotherapy with nimustine hydrochloride (ACNU) alone or with ACNU, procarbazine and vincristine. The median overall survival (OS) and progression-free survival times for all patients were 17.7 months [95% confidence interval (CI), 14.6-20.9 months] and 7.8 months (95% CI, 5.7-9.9 months), respectively. The 1-and 2-year survival rates were 67.2% and 33.7%, respectively. For patients treated with HDT, the median OS was 24.4 months (95% CI, 18.2-30.5 months), compared with 14.2 months (95% CI, 10.0-18.3 months) for those treated with CRT. The Cox proportional hazards model revealed radiation modality (HDT vs CRT) and European Organisation for Research and Treatment of Cancer recursive partitioning analysis class to be the significant prognostic factors. Age, sex, pre-operative performance status, treatment with or without advanced neuroimaging, extent of surgery and regimen of chemotherapy were not statistically significant factors in predicting prognosis. The median OS was 18.5 months (95% CI, 9.9-27.1 months) in patients of 65 years and older, compared with 16.8 months (95% CI, 13.6-20.1 months) in those 64 years and younger (p50.871). The positive effect of HDT treatment is unlikely to reflect patient selection alone. Randomised trials with strictly controlled inclusion criteria to ensure the comparable selection of patients are required to demonstrate conclusively that prolonged survival can be attributed to high-dose particle radiotherapies.

show abstract

Section: Discussioncontrasting

confidence: 60%

Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy

Matsuda¹,

Yamamoto²,

Ishikawa³

et al. 2011

BJR

View full text Add to dashboard Cite

show abstract

“…10 The trial had to be discontinued early because of the benefit observed in the radiotherapy group: the median survival for this group was 29.1 weeks (vs 16.9 weeks for the supportive care group), and there were no between-group differences in quality of life or the results of cognitive evaluations. The findings reported by Barnholtz-Sloan et al thus seem to confirm findings from other retrospective and prospective analyses suggesting that treatment of elderly patients with GBM employing multimodal therapies does lead to superior outcomes 2,14,15 without affecting their mental abilities or producing unbearable side effects.…”

supporting

confidence: 82%

Being old is no fun: treatment of glioblastoma multiforme in the elderly

Chiocca¹

2008

JNS

View full text Add to dashboard Cite

“…Previous studies have shown that patients who undergo biopsy only, have poorer survival rates than those who have had a surgical resection 13 .…”

Section: Discussionmentioning

confidence: 97%

Validation of an imageable surgical resection animal model of Glioblastoma (GBM)

Sweeney

Jarzabek

O’Brien

et al. 2014

Journal of Neuroscience Methods

View full text Add to dashboard Cite

Survival trends in elderly patients with glioblastoma multiforme: Resective surgery, radiation, and chemotherapy

Cited by 34 publications

References 18 publications

Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy

Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy

Being old is no fun: treatment of glioblastoma multiforme in the elderly

Validation of an imageable surgical resection animal model of Glioblastoma (GBM)

Contact Info

Product

Resources

About